

Joao Morais

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8811470/joao-morais-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11
papers

1,165
citations

9
h-index

12
g-index

12
ext. papers

1,356
ext. citations

6.9
avg, IF

3.38
L-index

#	Paper	IF	Citations
11	Identification of Clinically Relevant Rules: An Interpretable Approach for CVD Risk Assessment. <i>IFMBE Proceedings</i> , 2021 , 644-654	0.2	
10	The myth of stable coronary artery disease. <i>Nature Reviews Cardiology</i> , 2020 , 17, 9-21	14.8	39
9	Knowledge and Data Driven Approaches Applied to Clinical Assessment. <i>IFMBE Proceedings</i> , 2018 , 133-136		1
8	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2P-TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 164-172	4.3	7
7	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Thrombosis and the European Society of Cardiology Working Group on Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2213-2236	7	29
6	Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. <i>Circulation</i> , 2015 , 131, 1047-53	16.7	59
5	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventionalists (EAPCI), and the European Society of Cardiology Working Group on Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 3155-7	9.5	413
4	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1087-107	7	278
3	New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1413-25	15.1	211
2	Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012 , 14, 681-95	12.3	57
1	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 1009-22	7	49